by Dixie Lawrence | Sep 28, 2026 | Research
Rationale for the Use of Kaempferia parviflora (Black Ginger) as a Neuroprotective Anti-Inflammatory Agent Targeting Microglial Hyperactivity 1. Introduction and Clinical Need Chronic neuroinflammation driven by microglial hyperactivity is a primary pathophysiological...
by Dixie Lawrence | Sep 27, 2026 | Rationales, Uncategorized
Trisomy 21 Research Protocol for AD Very long post on the rational for the prevention of AD. This is NOT specific to DS but works in advanced AD in non DS patients as well. Note, not all substances utilized in TNI for DS are covered here. The science is so amazing....
by Dixie Lawrence | Sep 27, 2026 | Research
The most DS-specific target: RCAN1 RCAN1 (also called DSCR1) sits in the Down syndrome critical region on chromosome 21. Extra copy number raises RCAN1 protein, which: • increases mitochondrial and cellular ROS, • activates NF-κB, • induces the apoptosis adaptor...
by Dixie Lawrence | Sep 27, 2026 | Uncategorized
Note Dosing guidelines are very important as too much Hup A can increase urination. Do not exceed 1.5 mg per kg a day. Apigenin may be beneficial as an acetylcholinesterase inhibitor in persons who are sensitive to Hup A. Huperzine A and choline can support...
by Dixie Lawrence | Sep 27, 2026 | Research
Pathways and genes most likely to be affected 1. APP processing and amyloid pathology People with DS carry three copies of APP and develop Alzheimer-type plaques decades earlier than the general population. In APP/PS1 and 5xFAD mice, hesperidin. • reduces Aβ...